000 04023nam a22005655i 4500
999 _c200457979
_d76191
003 TR-AnTOB
005 20231109085846.0
007 cr nn 008mamaa
008 211219s2022 sz | s |||| 0|eng d
020 _a9783030878498
024 7 _a10.1007/978-3-030-87849-8
_2doi
040 _aTR-AnTOB
_beng
_erda
_cTR-AnTOB
041 _aeng
060 _aQZ 266
072 7 _aMBGR
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMBGR
_2thema
096 _aQZ266EBK
245 1 0 _aGene and Cellular Immunotherapy for Cancer
_h[electronic resource] /
_cedited by Armin Ghobadi, John F. DiPersio.
250 _a1st ed. 2022.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Humana,
_c2022.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development,
_x2196-9914
505 0 _aThe History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.
520 _aClinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.
650 0 _aMedicine—Research.
650 0 _aBiology—Research.
650 0 _aMedical microbiology.
650 0 _aPharmacology.
650 1 4 _aBiomedical Research.
650 2 4 _aMedical Microbiology.
650 2 4 _aPharmacology.
653 0 _aNeoplasms -- therapy
653 0 _aNeoplasms -- immunology
653 0 _aImmunotherapy
700 1 _aGhobadi, Armin.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aDiPersio, John F.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
830 0 _aCancer Drug Discovery and Development,
_x2196-9914
856 4 0 _uhttps://doi.org/10.1007/978-3-030-87849-8
_3Springer eBooks
_zOnline access link to the resource
942 _2NLM
_cEBK